PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the publication of a review of the current clinical development program for aclerastide (DSC127), a patented peptide analog of angiotensin, as a potential treatment for the closure of diabetic foot ulcers (DFUs) in an article titled, “NorLeu3-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers,” in the peer-reviewed journal, Advances in Wound Care. The full article can be accessed here or on the Company’s website at www.dermasciences.com.
“DSC127 and its active ingredient, NorLeu3-A(1-7), are potent stimulators of tissue repair and possibly regeneration leading to increased proportions of complete full-thickness wound healing. To date, DSC127 has been shown to be well tolerated in both preclinical and clinical studies.”
TIS Price at posting:
3.8¢ Sentiment: Sell Disclosure: Not Held
